Antimicrobial Strategies for Cystic Fibrosis

Abstract

Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication therapy, and long-term maintenance therapy based on inhaled antibiotics may be considered the main strategy for infection control in individuals with CF. While most of the existing evidence is based on infection with Pseudomonas aeruginosa, other important pathogens causing lung inflammation and deterioration exist and should be treated despite the evidence gap. In this chapter, we describe the approaches to the antimicrobial treatment of the most important pathogens in CF and the evidence behind.

Keywords

Pseudomonas aeruginosa - Staphylococcus aureus - nontuberculous mycobacteria - evidence - eradication - inhaled antibiotics

Publikationsverlauf

Artikel online veröffentlicht:
19. Dezember 2022

• References

• 1 Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 1938; 56 (02) 344-399
• 2 De Boeck K. Cystic fibrosis in the year 2020: a disease with a new face. Acta Paediatr 2020; 109 (05) 893-899
• 3 Castellani C, Duff AJA, Bell SC. et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros 2018; 17 (02) 153-178
• 4 Fibrosis MC. Concise clinical review managing cystic fibrosis. Am J Respir Crit Care Med 2011; 183: 1463-1471
• 5 Frederiksen B, Lanng S, Koch C, Høiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996; 21 (03) 153-158
• 6 Dutescu IA, Hillier SA. Encouraging the development of new antibiotics: are financial incentives the right way forward? A systematic review and case study. Infect Drug Resist 2021; 14: 415-434
• 7 Høiby N, Bjarnsholt T, Moser C. et al. Diagnosis of biofilm infections in cystic fibrosis patients. APMIS 2017; 125 (04) 339-343
• 8 Döring G, Conway SP, Heijerman HGM. et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16 (04) 749-767
• 9 Mogayzel Jr PJ, Naureckas ET, Robinson KA. et al; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013; 187 (07) 680-689
• 10 Heijerman H, Westerman E, Conway S, Touw D, Döring G. consensus working group. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009; 8 (05) 295-315
• 11 Döring G, Flume P, Heijerman H, Elborn JS. Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012; 11 (06) 461-479
• 12 Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009; 8 (02) 91-96
• 13 Møller R, Nielsen BU, Faurholt-Jepsen D. et al. Use of inhaled antibiotics among Danish patients with cystic fibrosis. Pediatr Pulmonol 2022; 57 (07) 1726-1734
• 14 Blasi F, Carnovale V, Cimino G. et al; FREE study group. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: the FREE study. Respir Med 2018; 138 (138) 88-94
• 15 Harrison MJ, McCarthy M, Fleming C. et al. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J Cyst Fibros 2014; 13 (06) 692-698
• 16 Barclay ML, Begg EJ, Chambers ST, Thornley PE, Pattemore PK, Grimwood K. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother 1996; 37 (06) 1155-1164
• 17 Loebinger MR, Polverino E, Chalmers JD. et al; iBEST-1 Trial Team. Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study. Eur Respir J 2021; 57 (01) 2001451
• 18 Zarogoulidis P, Kioumis I, Porpodis K. et al. Clinical experimentation with aerosol antibiotics: current and future methods of administration [Corrigendum]. Drug Des Devel Ther 2014; 8: 121
• 19 Orenti A, Zolin A, Jung A. et al. ECFS Patient Registry Annual Data Report 2019. Lung. 2021. Accessed October 03, 2022 at: http://www.cff.org/UploadedFiles/research/ClinicalResearch/Patient-Registry-Report-2009.pdf
• 20 Cystic Fibrosis Foundation. Cystic Fibrosis Foundation 2020 Annual. Data Rep 2021
• 21 Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34 (02) 91-100
• 22 Brazova J, Sediva A, Pospisilova D. et al. Differential cytokine profile in children with cystic fibrosis. Clin Immunol 2005; 115 (02) 210-215
• 23 Moser C, Jensen PØ, Pressler T. et al. Serum concentrations of GM-CSF and G-CSF correlate with the Th1/Th2 cytokine response in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. Acta Pathol Microbiol Scand Suppl 2005; 113 (06) 400-409
• 24 Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23 (05) 330-335
• 25 Saiman L, Siegel JD, LiPuma JJ. et al; Cystic Fibrous Foundation, Society for Healthcare Epidemiology of America. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014; 35 (Suppl. 01) S1-S67
• 26 Jones AM, Govan JR, Doherty CJ. et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001; 358 (9281): 557-558
• 27 Pedersen SS, Koch C, Høiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986; 17 (04) 505-516
• 28 Döring G, Hoiby N, Assael B. et al; Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004; 3 (02) 67-91
• 29 Taccetti G, Campana S, Festini F, Mascherini M, Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26 (03) 458-461
• 30 Spielman DB, Beswick DM, Kimple AJ. et al. The management of cystic fibrosis chronic rhinosinusitis: an evidenced-based review with recommendations. Int Forum Allergy Rhinol 2022; 12 (09) 1148-1183
• 31 Ratjen F, Munck A, Kho P, Angyalosi G. ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65 (04) 286-291
• 32 Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991; 338 (8769): 725-726
• 33 Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005; 4 (Suppl. 02) 49-54
• 34 Pressler T, Bohmova C, Conway S. et al. Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros 2011; 10 (Suppl. 02) S75-S78
• 35 Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Döring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007; 42 (03) 249-255
• 36 Ramsey BW, Pepe MS, Quan JM. et al; Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340 (01) 23-30
• 37 Ramsey BW, Dorkin HL, Eisenberg JD. et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 328 (24) 1740-1746
• 38 MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa . Pediatr Pulmonol 1989; 7 (01) 42-48
• 39 Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20 (03) 658-664
• 40 Jensen T, Pedersen SS, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987; 19 (06) 831-838
• 41 Schuster A, Haliburn C, Döring G, Goldman MH, Group FS. Freedom Study Group. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013; 68 (04) 344-350
• 42 McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178 (09) 921-928
• 43 Oermann CM, Retsch-Bogart GZ, Quittner AL. et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45 (11) 1121-1134
• 44 Elborn JS, Flume PA, Cohen F, Loutit J, VanDevanter DR. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. J Cyst Fibros 2016; 15 (05) 634-640
• 45 Bilton D, Pressler T, Fajac I. et al; CLEAR-108 Study Group. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Cyst Fibros 2020; 19 (02) 284-291
• 46 Szaff M, Høiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983; 72 (05) 651-657
• 47 Høiby N. New antimicrobials in the management of cystic fibrosis. J Antimicrob Chemother 2002; 49 (02) 235-238
• 48 Elborn JS, Prescott RJ, Stack BHR. et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000; 55 (05) 355-358
• 49 CF Center København Rigshospitalet. Antibiotikabehandling af bakterielle lungeinfektioner hos cystisk fibrose. 2009: 1-41
• 50 Esposito S, Pennoni G, Mencarini V, Palladino N, Peccini L, Principi N. Antimicrobial treatment of Staphylococcus aureus in patients with cystic fibrosis. Front Pharmacol 2019; 10 (JULY): 849
• 51 Sagel SD, Gibson RL, Emerson J. et al; Inhaled Tobramycin in Young Children Study Group, Cystic Fibrosis Foundation Therapeutics Development Network. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009; 154 (02) 183-188
• 52 Gangell C, Gard S, Douglas T. et al; AREST CF. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis 2011; 53 (05) 425-432
• 53 Cogen J, Emerson J, Sanders DB. et al; EPIC Study Group. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol 2015; 50 (08) 763-770
• 54 Pillarisetti N, Williamson E, Linnane B. et al; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011; 184 (01) 75-81
• 55 Simon RH. Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection - UpToDate. UpToDate. 2020;10:35. Accessed October 03, 2022 at: https://www.uptodate.com/contents/cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection/print?search=fibrose cística AND pseudomonas aeruginosa&source = search_result&selectedTitle = 1∼150&usage_type = default&display_rank = 1
• 56 Rosenfeld M, Rayner O, Smyth AR. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2020; 9 (04) CD001912
• 57 Ahmed MI, Mukherjee S, Mi A, Mukherjee S. Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis. Cochrane Database Syst Rev 2018; 7 (07) CD011581
• 58 Dalbøge CS, Pressler T, Høiby N, Nielsen KG, Johansen HK. A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF. J Cyst Fibros 2013; 12 (01) 42-48
• 59 Máiz L, Del Campo R, Castro M, Gutiérrez D, Girón R, Cantón Moreno R. Maintenance treatment with inhaled ampicillin in patients with cystic fibrosis and lung infection due to methicillin-sensitive Staphylococcus aureus . Arch Bronconeumol 2012; 48 (10) 384 (English Edition)
• 60 Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010; 303 (23) 2386-2392
• 61 Lo DKH, Muhlebach MS, Smyth AR. Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev 2018; 7 (07) CD009650
• 62 Dolce D, Neri S, Grisotto L. et al. Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: a randomized multicenter study. PLoS One 2019; 14 (03) e0213497
• 63 Muhlebach MS, Beckett V, Popowitch E. et al; STAR-too study team. Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. Thorax 2017; 72 (04) 318-326
• 64 Dezube R, Jennings MT, Rykiel M. et al. Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. J Cyst Fibros 2019; 18 (03) 357-363
• 65 Vanderhelst E, De Wachter E, Willekens J, Piérard D, Vincken W, Malfroot A. Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of 11 patients. J Cyst Fibros 2013; 12 (06) 662-666
• 66 Vallières E, Rendall JC, Moore JE. et al. MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis. ERJ Open Res 2016; 2 (01) 1-7
• 67 Macfarlane M, Leavy A, McCaughan J, Fair R, Reid AJM. Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J Hosp Infect 2007; 65 (03) 231-236
• 68 Hall H, Gadhok R, Alshafi K, Bilton D, Simmonds NJ. Eradication of respiratory tract MRSA at a large adult cystic fibrosis centre. Respir Med 2015; 109 (03) 357-363
• 69 Saliu F, Rizzo G, Bragonzi A. et al. Chronic infection by nontypeable Haemophilus influenzae fuels airway inflammation. ERJ Open Res 2021; 7 (01) 00614-2020
• 70 Vandenbranden SL, McMullen A, Schechter MS. et al; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatr Pulmonol 2012; 47 (02) 135-143
• 71 Chmiel JF, Aksamit TR, Chotirmall SH. et al. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc 2014; 11 (07) 1120-1129
• 72 Hansen CR, Pressler T, Nielsen KG, Jensen PØ, Bjarnsholt T, Høiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros 2010; 9 (01) 51-58
• 73 Regan KH, Bhatt J, Kh R, Bhatt J. Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev 2019; 4 (04) CD009876
• 74 Wang M, Ridderberg W, Hansen CR. et al. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. J Cyst Fibros 2013; 12 (06) 638-643
• 75 Br K. The Burkholderia cepacia Suggestions for Prevention and Infection Control The UK Cystic Fibrosis Trust Infection Control Group; 2013;(388213)
• 76 Garcia BA, Carden JL, Goodwin DL. et al. Implementation of a successful eradication protocol for Burkholderia cepacia complex in cystic fibrosis patients. BMC Pulm Med 2018; 18 (01) 35
• 77 Gruzelle V, Guet-Revillet H, Segonds C. et al. Management of initial colonisations with Burkholderia species in France, with retrospective analysis in five cystic fibrosis centres: a pilot study. BMC Pulm Med 2020; 20 (01) 159
• 78 Horsley A, Webb K, Bright-Thomas R, Govan J, Jones A. Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy?. Front Cell Infect Microbiol 2011; 1 (December): 18
• 79 Frost F, Shaw M, Nazareth D. Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev 2021; 12 (12) CD013079
• 80 Tullis DE, Burns JL, Retsch-Bogart GZ. et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros 2014; 13 (03) 296-305
• 81 Isler B, Kidd TJ, Stewart AG, Harris P, Paterson DL. Achromobacter infections and treatment options. Antimicrob Agents Chemother 2020; 64 (11) 1-16
• 82 Lambiase A, Catania MR, Del Pezzo M. et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2011; 30 (08) 973-980
• 83 De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros 2007; 6 (01) 75-78
• 84 Warner NC, Bartelt LA, Lachiewicz AM. et al. Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and Achromobacter xylosoxidans infections. Clin Infect Dis 2021; 73 (07) e1754-e1757
• 85 Waters V, Yau Y, Prasad S. et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011; 183 (05) 635-640
• 86 Dalbøge CS, Hansen CR, Pressler T, Høiby N, Johansen HK. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. J Cyst Fibros 2011; 10 (05) 318-325
• 87 Colin AA, Rabin HR. Stenotrophomonas maltophilia in cystic fibrosis: guilty or innocent?. Am J Respir Crit Care Med 2011; 183 (05) 564-566
• 88 Chalermskulrat W, Sood N, Neuringer IP. et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61 (06) 507-513
• 89 Binder AM, Adjemian J, Olivier KN, Prevots DR. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013; 188 (07) 807-812
• 90 Qvist T, Gilljam M, Jönsson B. et al; Scandinavian Cystic Fibrosis Study Consortium (SCFSC). Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst Fibros 2015; 14 (01) 46-52
• 91 Adjemian J, Olivier KN, Prevots DR. Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010-2014. Ann Am Thorac Soc 2018; 15 (07) 817-826
• 92 Floto RA, Olivier KN, Saiman L. et al; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016; 71 (Suppl. 01) i1-i22
• 93 Qvist T, Taylor-Robinson D, Waldmann E. et al. Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros 2016; 15 (03) 380-385
• 94 Esther Jr CR, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9 (02) 117-123
• 95 Hughes DA, Bokobza I, Carr SB. Eradication success for non-tuberculous mycobacteria in children with cystic fibrosis. Eur Respir J 2021; 57 (05) 10-13
• 96 Saint GL, Thomas MF, Zainal Abidin N, Langley RJ, Brodlie M, McNamara P. NTM Collaborators Group. Treating nontuberculous mycobacteria in children with cystic fibrosis: a multicentre retrospective study. Arch Dis Child 2022; 107 (05) 479-485
• 97 Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev 2020; 6: CD010004
• 98 Olivier KN, Griffith DE, Eagle G. et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med 2017; 195 (06) 814-823
• 99 Kidd TJ. Pseudomonas aeruginosa infection after CFTR restoration. One step back, one step forward. Am J Respir Crit Care Med 2017; 195 (12) 1550-1552
• 100 Trend S, Fonceca AM, Ditcham WG, Kicic A, Cf A. The potential of phage therapy in cystic fibrosis: essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways. J Cyst Fibros 2017; 16 (06) 663-670
• 101 Clokie MRJ, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage 2011; 1 (01) 31-45